CliffBio
biologic

Dupixent

dupilumab

Loss of exclusivityOctober 2030projected — 12-year biologic exclusivity estimate
CompanyRegeneron Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameDupixent
Active ingredientdupilumab
Strength200MG/1.14ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2018
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.